What is Abcodia?
Abcodia, through its subsidiary GENinCode plc, offers the ROCA Test, a pioneering blood test designed to assess the risk of ovarian cancer in women over 35 who carry BRCA1 or BRCA2 gene mutations. This innovative diagnostic provides a crucial option for ongoing surveillance for individuals seeking to delay preventative surgery. The ROCA Test is currently accessible via the NHS in select UK regions and privately in clinics in Cardiff and London, positioning Abcodia at the forefront of genetic risk assessment for ovarian cancer.
How much funding has Abcodia raised?
Abcodia has raised a total of $8.2M across 1 funding round:
Unspecified
$8.2M
Unspecified (2015): $8.2M with participation from Scottish Equity Partners, Cambridge Innovation Capital, Albion Ventures, and UCL Business PLC
Key Investors in Abcodia
Scottish Equity Partners
Scottish Equity Partners (SEP) is a leading growth equity investor focused on enterprise software and technology scaleup companies in the UK and Europe, providing capital and extensive resources to support their growth.
Cambridge Innovation Capital
Cambridge Innovation Capital (CIC) is a venture capital investor focused on intellectual property rich technology and life science businesses in the Cambridge ecosystem, committed to building leading businesses from brilliant technologies.
Albion Ventures
AlbionVC is the technology investment arm of Albion Capital Group LLP, managing venture funds and supporting visionary founders with long-term capital and scale-up expertise, primarily investing in high-growth B2B software and technology-enabled services companies.
What's next for Abcodia?
The substantial enterprise-level funding Abcodia has garnered, particularly the recent strategic investment, signals a phase of accelerated growth and market expansion. This capital infusion is expected to fuel further development of the ROCA Test, enhance its clinical accessibility across broader geographies, and potentially support research into other high-risk cancer indications. The company's focus on leveraging genetic data for proactive health management aligns with a growing trend in personalized medicine, suggesting a strong trajectory for future innovation and commercial success.
See full Abcodia company page
